JP2021527092A - １９−ノルｃ３，３−二置換ｃ２１−ｎ−ピラゾリルステロイドおよびその使用方法 - Google Patents

１９−ノルｃ３，３−二置換ｃ２１−ｎ−ピラゾリルステロイドおよびその使用方法 Download PDF

Info

Publication number
JP2021527092A
JP2021527092A JP2020569024A JP2020569024A JP2021527092A JP 2021527092 A JP2021527092 A JP 2021527092A JP 2020569024 A JP2020569024 A JP 2020569024A JP 2020569024 A JP2020569024 A JP 2020569024A JP 2021527092 A JP2021527092 A JP 2021527092A
Authority
JP
Japan
Prior art keywords
subject
compound
episode
weeks
dosing regimen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020569024A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021527092A5 (https=
Inventor
スティーブン ジェイ ケインズ，
ジェイムズ ジェイ． ドハーティ，
ハンダン グンドゥーズ−ブルース，
ジェフリー エム． ジョナス，
ロバート アルフォンソ ラサー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sage Therapeutics LLC
Original Assignee
Sage Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sage Therapeutics LLC filed Critical Sage Therapeutics LLC
Publication of JP2021527092A publication Critical patent/JP2021527092A/ja
Publication of JP2021527092A5 publication Critical patent/JP2021527092A5/ja
Priority to JP2023205211A priority Critical patent/JP2024028849A/ja
Priority to JP2025064902A priority patent/JP2025108553A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020569024A 2018-06-12 2019-06-12 １９−ノルｃ３，３−二置換ｃ２１−ｎ−ピラゾリルステロイドおよびその使用方法 Pending JP2021527092A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023205211A JP2024028849A (ja) 2018-06-12 2023-12-05 １９－ノルｃ３，３－二置換ｃ２１－ｎ－ピラゾリルステロイドおよびその使用方法
JP2025064902A JP2025108553A (ja) 2018-06-12 2025-04-10 １９－ノルｃ３，３－二置換ｃ２１－ｎ－ピラゾリルステロイドおよびその使用方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862684155P 2018-06-12 2018-06-12
US62/684,155 2018-06-12
US201962789329P 2019-01-07 2019-01-07
US62/789,329 2019-01-07
US201962841645P 2019-05-01 2019-05-01
US62/841,645 2019-05-01
PCT/US2019/036848 WO2019241442A1 (en) 2018-06-12 2019-06-12 A 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023205211A Division JP2024028849A (ja) 2018-06-12 2023-12-05 １９－ノルｃ３，３－二置換ｃ２１－ｎ－ピラゾリルステロイドおよびその使用方法

Publications (2)

Publication Number Publication Date
JP2021527092A true JP2021527092A (ja) 2021-10-11
JP2021527092A5 JP2021527092A5 (https=) 2022-06-16

Family

ID=67211854

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020569024A Pending JP2021527092A (ja) 2018-06-12 2019-06-12 １９−ノルｃ３，３−二置換ｃ２１−ｎ−ピラゾリルステロイドおよびその使用方法
JP2023205211A Pending JP2024028849A (ja) 2018-06-12 2023-12-05 １９－ノルｃ３，３－二置換ｃ２１－ｎ－ピラゾリルステロイドおよびその使用方法
JP2025064902A Pending JP2025108553A (ja) 2018-06-12 2025-04-10 １９－ノルｃ３，３－二置換ｃ２１－ｎ－ピラゾリルステロイドおよびその使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023205211A Pending JP2024028849A (ja) 2018-06-12 2023-12-05 １９－ノルｃ３，３－二置換ｃ２１－ｎ－ピラゾリルステロイドおよびその使用方法
JP2025064902A Pending JP2025108553A (ja) 2018-06-12 2025-04-10 １９－ノルｃ３，３－二置換ｃ２１－ｎ－ピラゾリルステロイドおよびその使用方法

Country Status (12)

Country Link
US (4) US20210338692A1 (https=)
EP (1) EP3806863A1 (https=)
JP (3) JP2021527092A (https=)
KR (1) KR20210021005A (https=)
CN (2) CN112533611A (https=)
AU (2) AU2019287491B2 (https=)
CA (1) CA3103421A1 (https=)
IL (1) IL279315A (https=)
MA (1) MA52894A (https=)
MX (2) MX2020013557A (https=)
SG (1) SG11202012344RA (https=)
WO (1) WO2019241442A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023504517A (ja) * 2019-12-05 2023-02-03 セージ セラピューティクス， インコーポレイテッド １９－ノルｃ３，３－二置換ｃ２１－ｎ－ピラゾリルステロイドおよびその使用方法

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2806877B2 (en) 2012-01-23 2025-01-29 Sage Therapeutics, Inc. Neuroactive steroid formulations comprising a complex of allopregnanolone and sulfobutyl ether beta-cyclodextrin
CA2882708A1 (en) 2012-08-21 2014-02-27 Sage Therapeutics, Inc. Methods of treating epilepsy or status epilepticus
KR102396328B1 (ko) 2013-04-17 2022-05-10 세이지 테라퓨틱스, 인크. 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
WO2016082789A1 (en) 2014-11-27 2016-06-02 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
EP3504189A1 (en) 2016-08-23 2019-07-03 Sage Therapeutics, Inc. A crystalline 19-nor c3, 3-disubstituted c21-n-pyrazolyl steroid
MA51046A (fr) 2017-12-08 2021-03-17 Sage Therapeutics Inc Dérivés de 21-[4-cyano-pyrazol-1-yl]-19-nor-pregan-3. alpha-ol-20-one deutérés pour le traitement de troubles du snc
EP4125921A1 (en) 2020-03-25 2023-02-08 Sage Therapeutics, Inc. Use of agents for treatment of respiratory conditions
KR20230041049A (ko) * 2020-07-20 2023-03-23 세이지 테라퓨틱스, 인크. 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드의 제형 및 이의 사용 방법
KR20230136599A (ko) * 2021-01-28 2023-09-26 세이지 테라퓨틱스, 인크. 성 기능장애의 치료를 위한 신경활성 스테로이드의용도
US20240245711A1 (en) * 2021-03-17 2024-07-25 Sage Therapeutics, Inc. A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid for the treatment of major depressive disorder
WO2022232504A1 (en) * 2021-04-29 2022-11-03 Sage Therapeutics, Inc. 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid for use in treating major depressive disorder and postpartum depression
EP4329769A1 (en) * 2021-04-29 2024-03-06 Sage Therapeutics, Inc. Neuroactive steroid for use in treating major depressive disorder and postpartum depression in a lactating female
IL315023A (en) * 2022-02-16 2024-10-01 Sage Therapeutics Inc Neuroactive steroids for treatment of cns-related disorders
WO2025175214A1 (en) * 2024-02-16 2025-08-21 Engrail Therapeutics, Inc. Methods of treating generalized anxiety disorder

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102396328B1 (ko) * 2013-04-17 2022-05-10 세이지 테라퓨틱스, 인크. 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법
JOP20200195A1 (ar) * 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
ME03809B (me) * 2014-10-16 2021-04-20 Sage Therapeutics Inc KOMPOZICIJE I POSTUPCI ZA LEČENJE POREMEĆAJA CNS-a
KR20240157128A (ko) * 2016-03-08 2024-10-31 세이지 테라퓨틱스, 인크. 신경활성 스테로이드, 조성물, 및 그의 용도
EP3504189A1 (en) * 2016-08-23 2019-07-03 Sage Therapeutics, Inc. A crystalline 19-nor c3, 3-disubstituted c21-n-pyrazolyl steroid
WO2019051264A1 (en) * 2017-09-07 2019-03-14 Sage Therapeutics, Inc. NEUROACTIVE STEROIDS AND METHODS OF USE

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GUNDUZ-BRUCE, H. ET AL.: "SAGE-217 in Subjects with Major Depressive Disorder: Efficacy and Safety Results from Open-label Par", 30TH ECNP CONGRESS, JPN7023002150, 2017, ISSN: 0005273600 *
GUNDUZ-BRUCE, H. ET AL.: "SAGE-217 in Subjects with Major Depressive Disorder: Efficacy and Safety Results from Open-label Par", EUROPEAN NEUROPSYCHOPHARMACOLOGY, vol. Vol.27, Supplement 4, JPN7023002151, 2017, pages 856 - 857, ISSN: 0005273599 *
JOURNAL OF MEDICINAL CHEMISTRY, vol. 60, JPN7023002149, 2017, pages 7810 - 7819, ISSN: 0005273601 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023504517A (ja) * 2019-12-05 2023-02-03 セージ セラピューティクス， インコーポレイテッド １９－ノルｃ３，３－二置換ｃ２１－ｎ－ピラゾリルステロイドおよびその使用方法

Also Published As

Publication number Publication date
CN112533611A (zh) 2021-03-19
JP2024028849A (ja) 2024-03-05
CN117959309A (zh) 2024-05-03
JP2025108553A (ja) 2025-07-23
MX2025000166A (es) 2025-03-07
AU2019287491B2 (en) 2025-05-15
IL279315A (en) 2021-01-31
US20210338692A1 (en) 2021-11-04
KR20210021005A (ko) 2021-02-24
US20250339447A1 (en) 2025-11-06
WO2019241442A1 (en) 2019-12-19
MA52894A (fr) 2021-04-21
TW202005653A (zh) 2020-02-01
EP3806863A1 (en) 2021-04-21
SG11202012344RA (en) 2021-01-28
CA3103421A1 (en) 2019-12-19
US20200113917A1 (en) 2020-04-16
AU2025217363A1 (en) 2025-09-04
MX2020013557A (es) 2021-05-27
AU2019287491A1 (en) 2021-01-07
US20220323462A1 (en) 2022-10-13

Similar Documents

Publication Publication Date Title
JP2021527092A (ja) １９−ノルｃ３，３−二置換ｃ２１−ｎ−ピラゾリルステロイドおよびその使用方法
US20240216395A1 (en) 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid for use in treating major depressive disorder and postpartum depression
US20230018765A1 (en) A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof
TW202128183A (zh) 用於治療多種病症之方法及組成物
US20250295674A1 (en) Neuroactive steroids for treatment of cns-related disorders
JP2026050474A (ja) Ｎｍｄａ拮抗薬の副作用の低減
KR20210153059A (ko) 중수소화 덱스트로메토르판 및 퀴니딘을 사용하는 정신분열병의 음성 증상의 치료 방법
JP2022519007A (ja) 脳性麻痺におけるジスキネジアを処置するためのデューテトラベナジン
TW202019425A (zh) 利用經取代胺基-嘧啶化合物治療及預防多發性硬化症之方法
RU2851101C2 (ru) 19-nor с3,3-замещенный с21-n-пиразолилстероид и способы его применения
WO2025257799A1 (en) Methods of treating dravet syndrome
EA044015B1 (ru) Дейтетрабеназин для лечения дискинезии при церебральном параличе
Malingering Deception Syndromes: Factitious Disorders and Malingering
Bukhari Pharmacy Registration Assessment Questions
EA051453B1 (ru) Способы лечения и профилактики рассеянного склероза с применением соединений замещенного аминопиримидина
WACHTER Sildenafil Found Beneficial in Pediatric PAH
Ferreira 1.5 CEUs

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220608

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220608

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230517

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230605

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230814

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231205

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240304